Insmed
Insmed's revenue rose 66.7% to $606 million in fiscal 2025. Its operating margin was −205.6%, up from −241.5% a year earlier. Free cash flow was −$968 million. The diluted share count rose 21.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Insmed lost money in fiscal 2025: a net loss of $1.3 billion.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 717 | 1,148 | 780 | 1,434 | 1,430 |
| Debt incl. finance leases | 815 | 1,185 | 1,207 | 1,149 | 571 |
| Net debt (negative means net cash) | 98 | 37 | 427 | −285 | −859 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 2.0x | 13.5x | — | 4.0x | 0.8x |
| Interest coverage | −9.3x | −17.3x | −8.7x | −10.3x | −14.9x |
| Current ratio | 6.2x | 6.7x | 4.1x | 5.5x | 3.8x |
| Quick ratio | 5.7x | 6.3x | 3.8x | 5.1x | 3.5x |
Cash flow
Projections
Project Insmed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Insmed shares on the open market, and 9 insiders sold $133.7 million, $83.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | David R BrennanDirector | Sold | 25,000 | $124.00 | $3.1 million | Form 4 |
| Aug 17, 2026 | Melvin Md SharokyDirector | Sold | 5,000 | $127.53 | $637,650 | Form 4 |
| Aug 10, 2026 | Roger AdsettChief Operating Officer | Sold | 239,850 | $133.27 | $32.0 million | Form 4 |
| Aug 6, 2026 | Martina M.D. FlammerChief Medical Officer | Sold plan | 27,173 | $128.61 | $3.5 million | Form 4 |
| Jul 23, 2026 | William LewisChair and CEO, Director | Sold plan | 10,700 | $106.06 | $1.1 million | Form 4 |
| Jul 9, 2026 | William LewisChair and CEO, Director | Sold plan | 10,699 | $117.40 | $1.3 million | Form 4 |
| Jul 6, 2026 | Martina M.D. FlammerChief Medical Officer | Sold plan | 12,302 | $109.98 | $1.4 million | Form 4 |
| Jun 25, 2026 | William LewisChair and CEO, Director | Sold plan | 21,398 | $103.32 | $2.2 million | Form 4 |
| Jun 22, 2026 | Michael Alexander SmithChief Legal Officer | Sold plan | 1,806 | $95.82 | $173,051 | Form 4 |
| Jun 8, 2026 | William LewisChair and CEO, Director | Sold plan | 6,515 | $94.03 | $612,605 | Form 4 |
| Jun 5, 2026 | Martina M.D. FlammerChief Medical Officer | Sold plan | 1,858 | $103.78 | $192,823 | Form 4 |
| Jun 3, 2026 | William LewisChair and CEO, Director | Sold | 7,605 | $102.27 | $777,763 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | −155.7% | −174.9% | −92.8% |
| Altman Z'' | −8.77 | −5.47 | −7.47 |
| Accruals ratio | −14.3% | −13.7% | −15.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Insmed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Insmed | FY25 | 66.7% | −205.6% | −159.6% | — | — | 5 | |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
| Axsome Therapeutics | FY25 | 65.5% | −26.1% | −14.7% | — | — | 4 | Compare |
| HUTCHMED (China) | FY25 | −13.0% | −7.1% | −14.4% | — | — | 4 | Compare |
| Ultragenyx Pharmaceutical | FY25 | 20.2% | −79.5% | −70.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 10 | 136 | 164 | 188 | 245 | 305 | 364 | 606 |
| Revenue growth | — | — | — | 1,287.6% | 20.5% | 14.6% | 30.2% | 24.4% | 19.2% | 66.7% |
| Gross profit | 0 | 0 | 7 | 112 | 124 | 144 | 190 | 240 | 278 | 484 |
| Research and development | 123 | 110 | 145 | 132 | 181 | 273 | 398 | 571 | 598 | 771 |
| Operating income | −173 | −189 | −307 | −235 | −265 | −375 | −457 | −710 | −878 | −1,247 |
| Net income | −176 | −193 | −324 | −254 | −294 | −435 | −482 | −750 | −914 | −1,277 |
| Diluted EPS (US$) | −2.85 | −2.89 | −4.22 | −3.01 | −3.01 | −3.88 | −3.91 | −5.34 | −5.57 | −6.42 |
| Diluted shares (millions) | 62 | 67 | 77 | 85 | 98 | 112 | 123 | 140 | 164 | 199 |
| Cash flow | ||||||||||
| Cash from operations | −147 | −160 | −258 | −251 | −219 | −363 | −400 | −536 | −684 | −935 |
| Capital expenditure | 4 | 3 | 13 | 42 | 6 | 7 | 10 | 13 | 22 | 33 |
| Free cash flow | −151 | −163 | −271 | −293 | −226 | −371 | −410 | −550 | −706 | −968 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 18 | 18 | 26 | 27 | 36 | 46 | 58 | 75 | 97 | 153 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 163 | 381 | 495 | 487 | 533 | 717 | 1,148 | 780 | 1,434 | 1,430 |
| Debt incl. finance leases | 55 | 55 | 450 | 471 | 466 | 815 | 1,185 | 1,207 | 1,149 | 571 |
| Total assets | 238 | 462 | 605 | 742 | 796 | 1,244 | 1,656 | 1,330 | 2,025 | 2,265 |
| Total liabilities | 84 | 101 | 396 | 481 | 520 | 833 | 1,568 | 1,662 | 1,740 | 1,526 |
| Shareholders' equity | 154 | 361 | 208 | 262 | 276 | 410 | 88 | −332 | 285 | 739 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 75.4% | 82.3% | 75.8% | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% |
| Operating margin | — | — | −3,124.9% | −172.4% | −161.3% | −199.0% | −186.4% | −232.5% | −241.5% | −205.6% |
| Net margin | — | — | −3,297.2% | −186.4% | −178.9% | −230.6% | −196.3% | −245.6% | −251.2% | −210.5% |
| Free cash flow margin | — | — | −2,756.2% | −214.6% | −137.2% | −196.6% | −167.2% | −180.1% | −194.1% | −159.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | 1,072.9% | −116.7% | −182.0% | −137.0% | −155.7% | −174.9% | −92.8% |
| Return on capital | −272.0% | −365.0% | −245.1% | −91.1% | −92.3% | −82.6% | −114.1% | — | — | — |
| Return on equity | −75.6% | −74.7% | −113.9% | −108.2% | −109.4% | −126.7% | −193.2% | — | — | −249.3% |
| Return on assets | −59.3% | −55.0% | −60.8% | −37.8% | −38.2% | −42.6% | −33.2% | −50.2% | −54.5% | −59.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |